C difficile risk
Oral Bioavailability


Defined criteria for use and/or important safety considerations. See below for more information.

  • Dosed as a sum of piperacillin and tazobactam (e.g. 3.375 g = 3 g piperacillin + 0.375 g tazobactam)

3.375 g IV q6h

See order set "Prolonged Piperacillin-Tazobactam Infusion for Intensive Care Patients"

CrCl > 30 mL/minCrCl 10 - 30 mL/minCrCl < 10 mL/minNo renal adjustment required2.25 g IV q6h2.25 g IV q8h

2.25 g IV q8-12h

  • Consider additional 0.75 g IV dose after dialysis on HD days

  • For invasive infections (e.g. VAP) use q8h dosing

2.25 g IV q12h

3.375 g IV q6h

General Information

Treatment of serious Gram-negative or polymicrobial infections, including mixed aerobic and anaerobic infections, where the use of other agents is not appropriate because of resistance, contraindications or adverse events

Broad spectrum agent with anti-pseudomonal activity.Used for severe infections including:

  • Hospital acquired pneumonia

  • Intra-abdominal/hepatobiliary infections

  • Multi-drug resistant UTIs

  • Febrile neutropenia

  • Poor CNS penetration, use alternative agent

  • Avoid for serious/invasive AmpC microorganisms (Citrobacter, Enterobacter infections), even if reported as susceptible

Significant interaction with high dose methotrexate. Avoid concurrent use.

Antimicrobial class: Ureidopenicillin with a beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Poor

Biliary penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.